| Accession | PRJCA025141 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Title | Peony Exploratory Analyses of Biomarker Changes - from baseline to surgical samples in HER2+ Breast Cancer patients | ||||||||
| Relevance | Medical | ||||||||
| Data types |
Transcriptome or Gene expression
Variation |
||||||||
| Organisms | Homo sapiens | ||||||||
| Description | One study evaluated patients with early-stage or locally advanced HER2-positive breast cancer who received pertuzumab plus docetaxel, trastuzumab (neoadjuvant therapy) before surgery, and pertuzumab plus trastuzumab after postoperative chemotherapy. The data of the randomized, multi-center, double-blind, placebo-controlled phase III study of zizumab (adjuvant therapy) were released at the conference, including HER2 FISH, HER2/3 mRNA and PIK3CA report data, and did not involve sequencing. | ||||||||
| Sample scope | Multiisolate | ||||||||
| Release date | 2024-04-10 | ||||||||
| Grants |
|
||||||||
| Submitter | Zhimin Shao (szm@163.com) | ||||||||
| Organization | Fudan University Cancer Hospital Ltd. | ||||||||
| Submission date | 2024-04-10 |
| Resource name | Description |
|---|